基于PTCy的异基因骨髓移植平台作为儿童及年轻成人重型再生障碍性贫血的可及性治愈替代方案
该单中心回顾性研究纳入31例≤21岁获得性重型再生障碍性贫血(SAA)患者(2014-2024年),接受基于移植后环磷酰胺(PTCy)的减低强度预处理单倍体骨髓移植(haplo-BMT)或匹配同胞供者骨髓移植(MSD-BMT),或标准治疗MSD-BMT。总生存率97%(PTCy组96%,SOC组100%),GVHD发生率低,PTCy组供者嵌合率高。结果表明基于PTCy的haplo-BMT是安全有效的治愈方法,支持其作为 frontline 选择。
要点
- 基于PTCy的haplo-BMT在儿童及年轻成人SAA中总生存率96%,GVHD发生率低。
- PTCy组实现稳健供者嵌合,而SOC组均为混合嵌合。
- 支持PTCy haplo-BMT作为SAA一线选项,即使有MSD可用。
核心结论
- 基于PTCy的减低强度预处理haplo-BMT是儿童及年轻成人初治和复发/难治SAA安全有效的治愈方法。
- 支持其作为一线选择,即使匹配同胞供者可用。
研究设计与样本
- 单中心回顾性研究,纳入2014-2024年31例≤21岁获得性SAA患者。
- PTCy组23例接受减低强度预处理haplo-BMT或MSD-BMT联合PTCy、吗替麦考酚酯和他克莫司。
- SOC组8例接受标准MSD-BMT联合环磷酰胺/抗胸腺细胞球蛋白预处理及钙调磷酸酶抑制剂/甲氨蝶呤GVHD预防。
主要发现
- 总生存率97%(PTCy组96%,SOC组100%)。
- PTCy组仅1例2级急性GVHD和1例广泛性慢性GVHD,SOC组1例广泛性慢性GVHD。
- 无患者发生克隆性造血。
- 晚期效应少见,仅1例月经功能障碍和BK病毒相关肾病。
- PTCy组实现稳健供者嵌合,SOC组均为混合嵌合。
临床怎么用
- 对于儿童及年轻成人SAA,基于PTCy的haplo-BMT可作为可及的治愈性一线替代方案。
- 即使有匹配同胞供者,也可考虑PTCy haplo-BMT。
局限性
- 单中心回顾性研究,样本量较小(31例)。
- PTCy组与SOC组样本量不均衡(23例 vs 8例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Severe aplastic anemia (SAA) is a life-threatening bone marrow failure syndrome. Allogeneic bone marrow transplantation (allo-BMT) is the most definitive curative treatment for SAA and is prioritized when matched sibling donors (MSDs) are available. Haploidentical BMT (haplo-BMT) with posttransplant cyclophosphamide (PTCy) has emerged as a promising alternative, expanding donor access while mitigating historically high rates of graft failure and graft-versus-host disease (GVHD). We report the outcomes of 31 consecutive pediatric, adolescent, and young adult patients (aged ≤21 years) with acquired SAA who underwent allo-BMT at a single institution (2014-2024). Patients with treatment-naïve (TN) and relapsed/refractory (R/R) SAA were included. Patients received reduced-intensity conditioning (RIC) haplo-BMT or MSD-BMT with PTCy, mycophenolate mofetil, and tacrolimus (PTCy cohort, n = 23), or standard-of-care (SOC) MSD-BMT with cyclophosphamide/antithymocyte globulin conditioning and calcineurin inhibitor/methotrexate-based GVHD prophylaxis (SOC cohort, n = 8). Overall survival was 97% (PTCy, 96%; SOC, 100%). GVHD rates were low, with only 1 case of grade 2 acute GVHD and 1 case of extensive chronic GVHD (cGVHD) in the PTCy group, and 1 case of extensive cGVHD in the SOC group. No patients developed clonal hematopoiesis. Late effects were infrequent, and limited to menstrual dysfunction and BK virus-associated nephropathy in 1 patient. Robust donor chimerism was achieved in the PTCy cohort, in contrast to uniformly mixed chimerism in the SOC group. These findings demonstrate that RIC haplo-BMT with PTCy is a safe and effective curative approach for pediatric patients with both R/R and TN SAA, supporting its use as a frontline option even when MSDs are available.
引用
- Dionysiou M, Ktena YP, Bonifant CL, et al. PTCy-based allo-BMT platform as a curative, accessible alternative for pediatric and young adult severe aplastic anemia. Blood Adv. 2026. PMID: 42269078. doi:10.1182/bloodadvances.2025019581
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。